Free Trial
NASDAQ:IOBT

IO Biotech Q1 2024 Earnings Report

IO Biotech logo
$0.05 0.00 (0.00%)
As of 04/7/2026

IO Biotech EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.37
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

IO Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

IO Biotech Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

IO Biotech's Q4 2025 earnings is estimated for Wednesday, May 13, 2026, based on past reporting schedules, with a conference call scheduled on Friday, May 15, 2026 at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

IO Biotech Earnings Headlines

Why Are Shares Of IO Biotech Plummeting?
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
IO Biotech Provides Corporate Update
See More IO Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IO Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IO Biotech and other key companies, straight to your email.

About IO Biotech

IO Biotech (NASDAQ:IOBT) ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, specializing in the development of novel immuno-oncology therapies. The company’s proprietary platform focuses on activating and sustaining anti-tumor immune responses by targeting the PD-L1 immune checkpoint. IO Biotech’s lead candidate, IO-VAC(R), is a peptide-based cancer vaccine designed to induce durable T-cell responses against PD-L1–expressing tumors.

Since its founding in 2013, IO Biotech has advanced IO-VAC(R) into multiple clinical trials, including Phase II studies in patients with metastatic melanoma. The company’s pipeline also explores combination regimens that pair its vaccine technology with established checkpoint inhibitors to enhance therapeutic efficacy. Research and development activities are conducted in Denmark, with ongoing collaborations and trial sites across Europe and North America to support global patient access.

IO Biotech is led by an experienced management team with deep expertise in immunology, oncology drug development and regulatory affairs. The company’s strategic focus remains on translating its innate immune-priming technology into differentiated cancer treatments and expanding its clinical footprint through partnerships and investigator-initiated studies.

View IO Biotech Profile